Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27804714 | 0.86 | HTR6 (0.51) | HTR6GAAMAPTGFERNOS1 | |
| SCHEMBL5211495 | 0.85 | PDK1 (0.55) | GAAMAPTGFERNOS3NOS1 | |
| SCHEMBL10647146 | 0.85 | MAPT (0.47) | GAAMAPTGFERNOS3NOS1 | |
| SCHEMBL27665907 | 0.85 | CFD (0.55) | CFDAURKBHTR6LOXL2GAA | |
| SCHEMBL3003205 | 0.85 | CFD (0.59) | CFDAURKBHTR6LOXL2GAA | |
| SCHEMBL13564689 | 0.84 | MAPT (0.46) | GAAMAPTGFERNOS3NOS1 | |
| SCHEMBL5212905 | 0.84 | MAPT (0.46) | GAAMAPTGFERNOS3NOS1 | |
| SCHEMBL11627789 | 0.84 | CSNK2A1 (0.54) | CFDGAAMAPTGFERNOS3 | |
| SCHEMBL5031452 | 0.84 | SIGMAR1 (0.60) | GAAMAPT | |
| SCHEMBL4505211 | 0.84 | GAA (0.55) | CFDGAAMAPTGFERNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | claimed |
| CN-101048383-A | Gonadotropin releasing hormone receptor antagonists | WYETH CORP (US) | 2007-10-03 | — | — | CN | claimed |
| CN-1075717-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-09-01 | — | — | CN | claimed |
| CN-106986857-B | Trk inhibiting compound | 小野药品工业株式会社 | 2019-07-05 | — | — | CN | disclosed |
| CN-109400597-A | A kind of protein degradation targeting chimera and preparation method and application based on VEGFR-2 inhibitor ABT-869 | 西安交通大学 | 2019-03-01 | — | — | CN | disclosed |
| CN-107868060-A | The quinolinones compound of 2 [3 (4 morpholinyl) Propylamino] 3 aryl 4 and its application | 沈阳药科大学 | 2018-04-03 | — | — | CN | disclosed |
| CN-107793369-A | The quianzolinones of 2 [2 (2 methoxyphenoxy) ethylamino-] 3 aryl 4 and its application | 沈阳药科大学 | 2018-03-13 | — | — | CN | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | disclosed |
| CN-103110951-A | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors | ALCON INC | 2013-05-22 | — | — | CN | disclosed |
| CN-103087078-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| CN-1732159-A | Pyrimidinone derivatives as therapeutic agents for the treatment of acute and chronic inflammatory, ischemic and remodelling pathologies | BAYER HEALTHCARE AG (DE) | 2006-02-08 | — | — | CN | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1130351-C | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2003-12-10 | — | — | CN | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| CN-1051079-C | Benzodiazepine * derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMA CO LTD (JP) | 2000-04-05 | — | — | CN | disclosed |
| CN-1246850-A | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2000-03-08 | — | — | CN | disclosed |
| CN-1129442-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-08-21 | — | — | CN | disclosed |
| CN-1075717-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-09-01 | — | — | CN | disclosed |
| CN-1074678-A | 1, the 5-benzodiazepine derivatives | GLAXO SPA (IT) | 1993-07-28 | — | — | CN | disclosed |